Moody Aldrich Partners LLC Has $6.33 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Moody Aldrich Partners LLC decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 18.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 110,558 shares of the biopharmaceutical company's stock after selling 24,954 shares during the period. Halozyme Therapeutics comprises 1.2% of Moody Aldrich Partners LLC's portfolio, making the stock its 29th largest holding. Moody Aldrich Partners LLC owned about 0.09% of Halozyme Therapeutics worth $6,328,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. GAMMA Investing LLC increased its stake in Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 254 shares during the period. Fifth Third Bancorp increased its stake in shares of Halozyme Therapeutics by 2.4% in the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company's stock worth $587,000 after acquiring an additional 261 shares during the last quarter. Private Advisor Group LLC raised its holdings in shares of Halozyme Therapeutics by 1.8% during the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company's stock worth $1,191,000 after acquiring an additional 412 shares in the last quarter. Juncture Wealth Strategies LLC boosted its position in Halozyme Therapeutics by 3.6% during the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company's stock valued at $690,000 after purchasing an additional 415 shares during the last quarter. Finally, Retirement Systems of Alabama grew its stake in Halozyme Therapeutics by 0.3% in the first quarter. Retirement Systems of Alabama now owns 165,881 shares of the biopharmaceutical company's stock valued at $6,748,000 after purchasing an additional 436 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded down $1.50 during midday trading on Thursday, hitting $49.30. The company's stock had a trading volume of 1,039,167 shares, compared to its average volume of 1,281,450. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. The stock's 50 day simple moving average is $58.19 and its 200 day simple moving average is $51.44. The stock has a market capitalization of $6.27 billion, a price-to-earnings ratio of 20.37, a PEG ratio of 0.49 and a beta of 1.27. Halozyme Therapeutics, Inc. has a fifty-two week low of $32.83 and a fifty-two week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. During the same period in the previous year, the business posted $0.68 EPS. The company's revenue for the quarter was up 4.7% on a year-over-year basis. As a group, research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the company's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares of the company's stock, valued at approximately $40,063,244.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Matthew L. Posard sold 9,881 shares of the firm's stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the transaction, the director now directly owns 69,874 shares of the company's stock, valued at $4,031,729.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Helen Torley sold 10,000 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at $40,063,244.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock valued at $5,169,834 in the last ninety days. Company insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and raised their price target for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Wells Fargo & Company cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. The Goldman Sachs Group increased their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a "neutral" rating in a research note on Monday, July 22nd. Cowen reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Finally, Benchmark reissued a "buy" rating and set a $60.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $60.44.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.